Press release

Press release

June 22, 2020

Follicum AB receives Notice of Allowance from the US Patent Office for the protection of the company’s peptides developed for the treatment of diabetes and its related complications

Follicum AB (“Follicum”) has received information that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance of the US patent application 16/666,960. The patent application covers the company’s peptides and their use for treatment of diabetes and diabetes-associated complications. The application is directed to new peptides from the company’s two […]

June 3, 2020

Follicum re-starts phase II study with FOL-005 for stimulation of hair growth and expands the number of study centres

Follicum AB (“Follicum” or the “company”) today announced that the clinical Phase IIa study with a cream-like formulation of FOL-005 will re-start, following a pause due to the Covid-19 pandemic. To increase the recruitment rate, a third study centre has been contracted. The study comprises approximately 200 male patients with hair loss who are treated […]

May 12, 2020

Follicum files international patent application conferring extended protection for the topical formulation of FOL-005 and other peptides

Follicum AB (“Follicum” or the “company”) announces that the company has filed an international patent application (PCT) covering the formulation of FOL-005 developed by the company. The patent application is based on new experimental data that supports the use of the formulation for peptides other than FOL-005. The formulation of FOL-005 intended for topical application […]

March 20, 2020

Follicum receives notification of upcoming approval in Europe of the company’s patent for new peptides in diabetes

Follicum AB (“Follicum”) announces that the company has today received a preliminary approval from the European Patent Office (EPO) of a patent application concerning the company’s new class of peptides that are being developed to treat diabetes. Follicum’s patent application with publication number EP 3 618 845 comprises new peptides and their use in the […]

March 18, 2020

Follicum pauses recruitment of patients in Phase II clinical trial of FOL-005 as a result of the ongoing COVID-19 pandemic

Follicum AB (“Follicum” or “the company”) today announces that the company has decided to temporarily suspend the phase II study of the drug candidate FOL-005 recently initiated in Germany. This is due to government recommendations in Germany in light of the ongoing outbreak of COVID-19. The company intends to resume the recruitment of patients for […]

January 31, 2020

Follicum receives Vinnova grant to study binding of company’s proprietary FOL peptides to pancreatic cell receptors

Follicum (“Follicum” or “the Company”) today announces that the company’s grant application to Vinnova to study binding of FOL peptides to receptors on pancreatic cells has been approved. Follicum is the coordinator of the project, which also includes Lund University and SARomics Biostructures. Parts of the project involve advanced analysis work to be performed at […]

December 17, 2019

Follicum annnouces positive human ex vivo data from preclinical diabetes studies of new class of FOL peptides

Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed […]